Perfil de judicialização no Rio Grande do Norte: impacto da insulina nos custos à saúde

Abstract

Introduction: Access to medicines represents the principle of public policies established by the components of Pharmaceutical Services. Still, the judicialization of medicines is growing, given the inability of the system or even lack of information on access. This study, therefore, aimed to analyze the different requests via court decisions for treatment alternatives to patients with diabetes in the state of Rio Grande do Norte between 2013 and 2017. Methodology: This is a cross-sectional view of a larger exploratory study, CAAE 79763617.4.0000.5292. Results: A total of 987 patients requested medication through the judicial route, 108 of them eligible for this study. Of these, 55.45% reside in the Central Potiguar mesoregion and 27.32% of the lawsuits took place in 2015. The most requested judicialized medications were insulin glargine (35.58%), insulin lispro (14.42%) and insulin aspart (8.17%). In addition to the drugs present in RENAME: glibenclamide, gliclazide, NPH insulin, regular insulin and metformin, representing a total of 9.61% of requests. Following the ICD-10 category, endocrine, nutritional and metabolic diseases accounted for 94.74% of cases involving judicialization of antidiabetic drugs. Conclusion: The study concluded that there was an increase in lawsuits by the defense system, in addition to increased requests for insulin glargine and number of cases requested from patients in the central mesoregion.